Biotech Values

[DewDiligence]

VPHM’s HCV-796 is now officially dead:

http://www.thestreet.com/print/story/10412339.html

Of course, serious biotech investors already knew this compound was not coming back. Elevated liver enzymes in a drug to treat a serious liver disease is not a benign side effect, regardless of how hard a company tries to convince investors to the contrary.